Full Breakdown
Efficacy of 2024-2025 COVID Vaccines in Reducing Severe Outcomes
10/10/2025, 7:59:20 PM
Overview of Vaccine Effectiveness
A recent study published in the *New England Journal of Medicine* analyzed data from nearly 300,000 U.S. veterans to assess the effectiveness of the 2024-2025 mRNA COVID vaccines, specifically those from Pfizer (COMIRNATY) and Moderna (Spikevax). The findings indicate that these vaccines significantly reduced the risk of emergency department visits by 29%, hospitalizations by 39%, and deaths by 64% compared to unvaccinated individuals. The study included 164,132 veterans who received both COVID and flu vaccines and 131,839 who received only the flu vaccine, tracking their health outcomes over six months.
Key Findings
The overall effectiveness of the COVID vaccines was reported at 28%, aligning them with the efficacy of annual flu shots, which typically range from 30% to 60% in preventing severe illness or death. Notably, the vaccines demonstrated more pronounced benefits for older adults, particularly those aged 65 and older, who experienced nearly 40% effectiveness, compared to 27% for younger adults under 65. The study's authors emphasized that while the vaccines provide additional protection, the severity of COVID-related outcomes has decreased over time due to prior infections and vaccinations.
Criticism & Opposition
Despite the study's robust findings, experts have raised concerns about the declining uptake of COVID vaccines. Only 21% of U.S. adults received the previous year's vaccine, and current uptake for the 2024-2025 vaccines stands at just 3.7%. Critics, including Dr. Michael Mina, an immunologist, noted that the study's age categorization lacked granularity, making it difficult to assess the necessity of boosters for younger, healthy individuals. Additionally, the recent shift in CDC guidelines, which now require individuals under 65 to consult healthcare providers before vaccination, has led to confusion and may deter vaccination efforts.
Official Statements & Responses
The Centers for Disease Control and Prevention (CDC) has recommended COVID vaccinations for adults aged 65 and older and for those with underlying health conditions. However, the agency has stated that vaccination for healthy individuals over six months old should be based on shared clinical decision-making. Dr. Jesse Goodman, a former chief scientist at the FDA, affirmed that the vaccines still provide meaningful protection against severe outcomes, despite the waning effectiveness observed over time.
Conflicting Reports & Gaps
While the study indicates a significant reduction in severe outcomes due to vaccination, some experts argue that the benefits for younger adults remain unclear. The CDC's new guidance has sparked debate over the necessity of vaccination for this demographic, with some officials calling for more data to clarify the risk-benefit ratio for healthy individuals under 65.
Verbatim Quotes
- “The vaccines are still providing additional, not perfect, protection against meaningful outcomes, including hospitalization and death, even though such severe outcomes are now much less common overall than early in the pandemic,” — Dr. Jesse Goodman, Georgetown Medical Center
- “Each person in certain risk categories, especially the younger individuals, should have a discussion with their doctor,” — Dr. Michael Mina, Harvard T.H. Chan School of Public Health
- “The core message of this is that even now, with all of this vaccine-induced immunity and convalescent immunity floating around, there is still a measurable benefit,” — Dr. Bill Hanage, Harvard T.H. Chan School of Public Health
- “Given what we know about the risk of vaccination in this (middle-age and older) population, which is extremely low, these data suggest that, at least at that point when the study was performed, vaccination remained an attractive option,” — Dr. Eric Rubin, NEJM editor-in-chief
The study underscores the ongoing relevance of COVID vaccinations in preventing severe disease outcomes, particularly for vulnerable populations, while highlighting the need for clear communication regarding vaccination guidelines.
